EZElvin Zengin

Elvin Zengin

*This is an algorithmically generated author record based on publicly available information.

Elvin Zengin has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Christoph Sinning

    Univ Med Ctr Hamburg Hosp Eppendorf, Univ Heart & Vasc Ctr Hamburg, Dept Cardiol, D-20246 Hamburg, Germany

    4 shared publications
  • Stefan Blankenberg

    Univ Med Ctr Hamburg Hosp Eppendorf, Univ Heart & Vasc Ctr Hamburg, Dept Cardiol, D-20246 Hamburg, Germany

    4 shared publications
  • Carsten Rickers

    Univ Med Ctr Hamburg Hosp Eppendorf, Univ Heart & Vasc Ctr Hamburg, Adult Congenital Heart Dis Sect, Hamburg, Germany

    3 shared publications
  • Yskert von Kodolitsch

    Univ Med Ctr Hamburg Hosp Eppendorf, Univ Heart & Vasc Ctr Hamburg, Dept Cardiol, D-20246 Hamburg, Germany

    3 shared publications
  • C. Sinning

    Department of General and Interventional Cardiology, Germany

    2 shared publications
  • Christoph Sinning

    Department of Cardiology, University Heart and Vascular Centre Hamburg, University Medical Centre Hamburg-Eppendorf, Member of the German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Luebeck, Hamburg, Germany

    2 shared publications

Latest Publications

  • Open Access

    Temporal trends, patient characteristics and hospital volume outcomes after alcohol septal ablation and septal myectomy for treatment of obstructive hypertrophic cardiomyopathy

    by P M Becher, J Weimann, F Brunner, E Zengin-Sahm, M Remmel, B Schrage, M Patten, C Detter, H Reichenspurner, P Kirchhof, et al.

    Background: Hypertrophic obstructive cardiomyopathy (HOCM) represents a clinically and morphologically diverse hereditary cardiac disease that is frequently associated with poor prognosis. Nationwide data on septal reduction therapy (SRT), alcohol septal ablation (ASA) and septal myectomy (SM), remains scarce. The aim of this study was to investigate (i) temporal trends, (ii) patient characteristics, (iii) in-hospital outcomes, and associations between institutional procedural volumes and outcomes after ASA and SM in a large-scale nationwide cohort. Methods: Using data from the German Federal Bureau of Statistics, this study analyzed all patients with HOCM who were hospitalized for ASA or SM in a nationwide inpatient database in Germany between January 1, 2006, through December 31, 2019. Rates of adverse in-hospital events (in-hospital mortality, need for permanent pacemaker) were examined. Multivariate logistic regression analysis was performed to compare overall outcomes after each procedure based on tertiles of hospital volumes of ASA and SM. Results: A total of 8,514 patients underwent SRT, of whom 5,293 (62.2%) underwent ASA and 3,221 (37.8%) SM. Annual numbers for SM and ASA steadily increased over time: ASA procedures increased from 329 in 2006 to 451 in 2019 and SM procedures increased from 191 in 2006 to 222 in 2019, respectively. Patients with SM were older (mean 67.4 vs. 60.2 years), less likely female (56.4% vs. 49.9%), and had a higher burden of comorbidities (e.g., diabetes, atrial fibrillation, heart failure, chronic kidney disease) compared to patients with ASA. Over an observational period of 14 years, the majority of both ASA and SM procedures were performed at hospitals in the lowest volume category (≤20 procedures). The overall in-hospital mortality was higher in patients with SM (6.8%) compared to patients with ASA (0.8%), whereas the need for pacemaker implantation was more often observed in patients with ASA (19.3% vs. 13.1%; p<0.001). The lowest tertile of SM volume among hospitals was independently associated with an increased risk of in-hospital mortality (adjusted odds ratio (lowest vs. highest tertile), 2.64; 95% confidence interval, 1.49-4.66), whereas being in the lowest vs. the highest tertile of ASA by volume was not independently associated with risk of in-hospital mortality and adverse events. Conclusion: In this contemporary cohort with more than 8,500 cases of SRT between 2006 and 2019, the majority of SRT was performed at centers with a low volume of SM and ASA procedures. Low SM volume was independently associated with increased in-hospital mortality, whereas low ASA volume was not associated with adverse outcomes. Our findings may help to further understand how institutional SRT procedural volumes affects outcomes and might encourage referral of patients with HOCM to centers of excellence for SRT.


  • Open Access

    Outcome of pregnancy in a contemporary cohort of adults with congenital heart disease—a 10-year, single-center experience

    by Betül Toprak, Katharina Govorov, Katinka Kurz, Dora Csengeri, Jessica Weimann, Dennis Witte, Kurt Hecher, Bettina Hollwitz, Anne Hansen, Carsten Rickers, et al.

    Outcome of pregnancy in a contemporary cohort of adults with congenital heart disease—a 10-year, single-center experience Betül Toprak, Katharina Govorov, Katinka Kurz, Dora Csengeri, Jessica Weimann, Dennis Witte, Kurt Hecher, Bettina Hollwitz, Anne Hansen, Carsten Rickers, Christina Magnussen, Yskert von Kodolitsch, Tanja Zeller, Stefan Blankenberg, Christoph Sinning, Paulus Kirchhof, Elvin Zengin-Sahm


  • Open Access

    Heart failure in adults with congenital heart disease: a narrative review

    by Elvin Zengin, Christoph Sinning, Christopher Blaum, Stefan Blankenberg, Carsten Rickers, Yskert von Kodolitsch, Paulus Kirchhof, Nigel E. Drury, Victoria M. Stoll

    The number of adults with congenital heart disease (ACHD) has increased over the last decades due to advancements in medical care, including interventional and surgical therapies. We are therefore more frequently challenged by the long-term consequences of palliative or corrective surgery carried out during childhood. Although patients with ACHD may develop conditions related to general cardiovascular risk factors, such as coronary artery disease, the most common complications leading to morbidity and mortality are arrhythmias, heart failure and thromboembolic events. For the management of arrhythmias, current recommendations regarding ablation and device therapy must be considered, whilst also taking into account the anatomical limitations of their congenital heart defect or surgical pathways. Heart failure treatment in acute and chronic settings must also consider the particular anatomy present, including the nature of the systemic ventricle. Treatments strategies for ACHD are typically extrapolated from the respective guidelines in non-ACHD patients, despite a lack of evidence to support this strategy. Right heart failure can be especially challenging to manage in conditions where either a systemic right ventricle or shunt lesions resulting in volume and/or pressure loading of the right ventricle are present. All physicians and cardiologists in particular should be acquainted with the most common diseases in ACHD, their complications and management regime, especially with regards to heart failure as this is a common reason for acute presentation in the emergency department.


  • Open Access

    Marfan Syndrome Versus Bicuspid Aortic Valve Disease: Comparative Analysis of Obstetric Outcome and Pregnancy-Associated Immediate and Long-Term Aortic Complications

    by Betül Toprak, Katalin Szöcs, Elvin Zengin-Sahm, Christoph Sinning, Amra Hot, Peter Bannas, Kurt Hecher, Bernd Hüneke, Thomas S. Mir, Meike Rybczynski, et al.

    Pregnancy poses a threat to women with aortopathy. Conclusive data on the obstetric and aortic outcome in this risk collective, especially when it comes to aortic complications in the long term, are still missing. This study offers a comparative analysis of pregnancy-associated outcome in 113 consecutive women with Marfan syndrome or bicuspid aortic valve disease, including 46 ever-pregnant and 37 never-pregnant women with Marfan syndrome, and 23 ever-pregnant and 7 never-pregnant females with bicuspid aortic valve disease. The overall obstetric outcome was comparable between ever-pregnant women with Marfan syndrome and with bicuspid aortic valve disease (p = 0.112). Pregnancy-associated aortic dissection occurred in two women with Marfan syndrome (3%) during a total of 62 completed pregnancies, whereas no single case of aortic event occurred in women with bicuspid aortic valve disease during a total of 36 completed pregnancies (p = 0.530). In the long-term follow-up, aortic dissection occurred in 21% of ever-pregnant women with Marfan syndrome, but in none of the women with bicuspid aortic valve disease (p = 0.022). Proximal aortic surgery was performed with similar frequency in ever-pregnant women with Marfan syndrome and with bicuspid aortic valve disease in the long term (p = 0.252). However, ever-pregnant women with Marfan syndrome were younger when surgery was performed (44 ± 9 vs. 59 ± 7 years; p = 0.041). In Marfan syndrome, long-term growth of the aorta was comparable between ever-pregnant and never-pregnant women. Pregnancy thus exhibited an increased immediate aortic risk only in women with Marfan syndrome, but not in women with bicuspid aortic valve disease. Previous pregnancy did not relate to an increased long-term risk of adverse aortic events in women with Marfan syndrome or with bicuspid aortic valve disease.


  • Pregnancy in adults with congenital heart disease

    by Elvin Zengin, Götz Mueller, Stefan Blankenberg, Yskert von Kodolitsch, Carsten Rickers, Christoph Sinning

    Congenital heart disease (CHD) is present in 0.8–0.9% of live births. Prevalence of CHD is constantly increasing during the last decades in line with the treatment options for patients ranging from the surgical as well to the interventional spectrum. Most of the women with underlying CHD reach adulthood due to excellent surgical and interventional treatment options and most of them desire pregnancy. In Western countries, maternal heart disease is the major cause of mortality during pregnancy, thus risk estimation should be therefore individualized depending on the underlying CHD, functional class and treatment options. Pre-pregnancy counselling is mandatory in all women, especially in patients with high risk but even in patients with low risk, a plan for labor and delivery should be outlined in a heart pregnancy team. This review addresses the key element of pre-counselling, planning and successful disease management in patients with CHD during pregnancy.


  • Open Access

    Endocarditis of an ASD Occluder Mimicking Adult-onset Still Disease in a Grown-up with Congenital Heart Disease

    by Christoph Sinning, Benedikt Schrage, Götz C Müller, Elvin Zengin

    The case describes the endocarditis of an ASD occluder in a grown-up with congenital heart disease. The patient was at first treated as Adult-onset Still disease because of an infection with unkown focus. Due to the immunosuppressive therapy the infection was at first not related to the endocarditis. After treatment symptoms and signs of Adult-onset Still disease completely vanished.

  • Right heart failure in pregnant women with cyanotic congenital heart disease — The good, the bad and the ugly

    by E. Zengin, C. Sinning, B. Schrage, G.C. Mueller, H. Klose, J. Sachweh, M. Goepfert, B. Hueneke, S. Blankenberg, R. Kozlik-Feldmann


  • The Utility of Pregnancy-Associated Plasma Protein a for Determination of Prognosis in a Cohort of Patients With Coronary Artery Disease

    by Elvin Zengin, Christoph Sinning, Tanja Zeller, Hans-J Rupprecht, Renate B Schnabel, Karl-J Lackner, Stefan Blankenberg, Dirk Westermann, Christoph Bickel, for the AtheroGene Study investigators

    Background: Pregnancy-associated plasma protein-A (PAPP-A) is discussed as a biomarker representing unstable plaques in coronary artery disease (CAD). Methods: In this study 927 patients with CAD (534 with stable angina and 393 with acute coronary syndrome [ACS]) and 217 patients without CAD and measured PAPP-A levels were included. Follow-up for a median of 5 years was documented. Results: Rising quartiles of PAPP-A concentration had a higher cardiovascular mortality in the overall cohort of patients with CAD (p = 0.002) and the cohort with ACS (p = 0.01). Patients with suspected ACS below the LOD for troponin I but elevated PAPP-A levels had an increased cardiovascular mortality. A cut-off of 11.4 IU/l identified patients with a higher mortality during follow-up. Conclusion: Rising PAPP-A levels are prognostic in patients with CAD. PAPP-A levels were especially predictive in ACS patients with troponin below 10% CV of the 99th percentile for cardiovascular mortality.